This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ProMIS Neurosciences Croissance future

Future contrôle des critères 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for ProMIS Neurosciences.

Informations clés

9.3%

Taux de croissance des bénéfices

13.3%

Taux de croissance du BPA

Biotechs croissance des bénéfices	36.6%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	17 Jul 2023

Mises à jour récentes de la croissance future

Recent updates

We're A Little Worried About ProMIS Neurosciences' (TSE:PMN) Cash Burn Rate

Oct 11

Despite Lacking Profits ProMIS Neurosciences (TSE:PMN) Seems To Be On Top Of Its Debt

Jun 23

Is ProMIS Neurosciences (TSE:PMN) A Risky Investment?

Mar 07

Is ProMIS Neurosciences (TSE:PMN) A Risky Investment?

Nov 19

Prévisions de croissance des bénéfices et des revenus

TSX:PMN - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2025	N/A	-18	N/A	N/A	1
12/31/2024	N/A	-14	N/A	N/A	1
12/31/2023	N/A	-17	N/A	N/A	1
3/31/2023	N/A	-21	-16	-16	N/A
12/31/2022	N/A	-18	-17	-17	N/A
9/30/2022	0	-12	-16	-16	N/A
6/30/2022	0	-8	-15	-15	N/A
3/31/2022	N/A	-6	-12	-12	N/A
12/31/2021	N/A	-10	-9	-9	N/A
9/30/2021	N/A	-8	-6	-6	N/A
6/30/2021	N/A	-8	-4	-4	N/A
3/31/2021	0	-9	-3	-3	N/A
12/31/2020	0	-4	-4	-3	N/A
9/30/2020	0	-5	-4	-4	N/A
6/30/2020	0	-5	-4	-4	N/A
3/31/2020	0	-5	-4	-4	N/A
12/31/2019	0	-6	-5	-5	N/A
9/30/2019	0	-7	-6	-6	N/A
6/30/2019	0	-8	-7	-7	N/A
3/31/2019	0	-8	-7	-7	N/A
12/31/2018	0	-7	-6	-6	N/A
9/30/2018	0	-6	-6	-6	N/A
6/30/2018	0	-5	-5	-5	N/A
3/31/2018	0	-5	-5	-5	N/A
12/31/2017	0	-5	-5	-5	N/A
9/30/2017	0	-5	-4	-4	N/A
6/30/2017	0	-4	-3	-3	N/A
3/31/2017	0	-3	-3	-3	N/A
12/31/2016	0	-3	N/A	-2	N/A
9/30/2016	0	-2	N/A	-2	N/A
6/30/2016	0	-2	N/A	-2	N/A
3/31/2016	0	-2	N/A	-2	N/A
12/31/2015	0	-2	N/A	-1	N/A
9/30/2015	0	-1	N/A	-1	N/A
6/30/2015	0	-2	N/A	-1	N/A
3/31/2015	0	-2	N/A	-1	N/A
12/31/2014	0	-2	N/A	-2	N/A
9/30/2014	0	-3	N/A	-2	N/A
6/30/2014	0	-2	N/A	-2	N/A
3/31/2014	0	-2	N/A	-2	N/A
12/31/2013	0	-2	N/A	-1	N/A
9/30/2013	0	-2	N/A	-1	N/A
6/30/2013	0	-2	N/A	-2	N/A
3/31/2013	0	-2	N/A	-2	N/A
12/31/2012	0	-2	N/A	-2	N/A
9/30/2012	0	-3	N/A	-3	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: PMN is forecast to remain unprofitable over the next 3 years.

Bénéfices vs marché: PMN is forecast to remain unprofitable over the next 3 years.

Croissance élevée des bénéfices: PMN is forecast to remain unprofitable over the next 3 years.

Chiffre d'affaires vs marché: Insufficient data to determine if PMN's revenue is forecast to grow faster than the Canadian market.

Croissance élevée des revenus: PMN is forecast to have no revenue next year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if PMN's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

ProMIS Neurosciences Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

No longer forecast to breakeven

Recent updates

ProMIS Neurosciences to Delist from TSX

ProMIS Neurosciences Inc. Announces FDA Clearance of Investigational New Drug Application for PMN310 in Alzheimer’s Disease

No longer forecast to breakeven

ProMIS Neurosciences, Inc. announced that it has received $7.472277 million in funding from Kraft Group LLC and other investors

We're A Little Worried About ProMIS Neurosciences' (TSE:PMN) Cash Burn Rate

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. to Present At 2022 Alzheimer's Association International Conference

ProMIS Neurosciences Common Shares Deleted from Other OTC

Chairman & CEO recently bought CA$64k worth of stock

Despite Lacking Profits ProMIS Neurosciences (TSE:PMN) Seems To Be On Top Of Its Debt

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

Full year 2021 earnings: EPS misses analyst expectations

Is ProMIS Neurosciences (TSE:PMN) A Risky Investment?

ProMIS Neurosciences, Inc. Announces Pmn310 Antibody Demonstrates Significant Cognitive Benefit in A Mouse Model of Alzheimer’s Disease

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences, Inc. Initiates Program to Develop Monoclonal Antibodies to Treat Schizophrenia and Other Chronic Mental Illnesses

Is ProMIS Neurosciences (TSE:PMN) A Risky Investment?

ProMIS Neurosciences, Inc. has completed a Composite Units Offering in the amount of $17.5 million.

ProMIS Neurosciences, Inc. Initiates Commercialization of Covid-19 Serology Assay

ProMIS Neurosciences Re-Initiates Path to IND for PMM310 with Producer Cell Line Development

Full year 2020 earnings released: CA$0.02 loss per share (vs CA$0.028 loss in FY 2019)

ProMIS Neurosciences, Inc. announced that it has received CAD 8.75 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences, Inc. Announces Perspectives on Recent Progress in the Alzheimer's Field

Earnings miss expectations

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

ProMIS Neurosciences, Inc. Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

ProMIS Neurosciences, Inc. Announces Resignation of Anthony Giovinazzo from the Board of Directors

ProMIS Neurosciences, Inc. to Develop Multivalent Vaccine for Alzheimer’s Disease

Earnings released

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance